Cellebrite DI Ltd. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 filing. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars.
Business context
Cellebrite sells digital investigative software and services, including digital forensics, evidence management and investigative analytics, mainly to government and law-enforcement customers. Its Case-to-Closure platform serves approximately 7,000 customers. Public-sector customers generated more than 90% of 2023 revenue; no single customer contributed more than 5%, while the top 25 contributed 26%.
Key financial results
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $325.1 million | $270.7 million |
| Gross profit / margin | $271.9 million / 84% | $219.9 million / 81% |
| Operating income | $33.2 million | $1.0 million |
| Net income (loss) | $(81.1) million | $120.8 million |
| Adjusted EBITDA / margin | $61.9 million / 19% | $25.9 million / 10% |
| Cash provided by operating activities | $102.1 million | $20.6 million |
- Revenue increased 20%. Subscription revenue rose 30% to $280.4 million, including subscription services up 37%; other non-recurring revenue fell 37% to $13.6 million, and professional-services revenue fell 7% to $31.1 million. Subscription licenses represented 86% of annual revenue.
- Operating expenses increased 9% to $238.6 million, led by 14% growth in sales and marketing. Research and development expense was $84.4 million.
- The GAAP net loss primarily reflects $119.3 million of expense from fair-value remeasurement of warrants, restricted sponsor shares and price-adjustment shares. These instruments produced substantial gains in 2022; operating income and Adjusted EBITDA improved in 2023.
- ARR was $316 million, up 27% from $249 million; recurring-revenue dollar-based net retention was 125%, down from 130%. Reported net churn was 10%.
- At year-end, cash and cash equivalents were $189.5 million, short-term deposits $74.7 million and marketable securities $67.6 million, totaling $331.8 million. The company reported no outstanding debt and no credit facilities. Current liabilities were $253.8 million, including $195.7 million of deferred revenue.
- Investing activities used $22.5 million and financing activities provided $21.8 million. Capital expenditures were $7.9 million. Lease commitments were $15.5 million.
Changes, outlook and management commentary
Management attributed growth to sales to existing customers and broader adoption of its offerings. It expects existing liquidity and operating cash flows to fund organic operations and capital expenditures for at least 12 months; it may seek financing for acquisitions or other inorganic growth. No formal numerical revenue or earnings guidance is provided in the filing.
For 2024, stated priorities include migrating customers to Inseyets, growing Guardian and Pathfinder adoption, expanding private-sector sales, and developing cloud-based offerings. Management cited customer expansion as a growth driver, while retention eased year over year.
Risks, contingencies and unusual items
- Government and law-enforcement agencies account for over 90% of revenue. Procurement delays, budget constraints, contract termination and changes in spending priorities could affect results; U.S. federal customers accounted for 17% of 2023 revenue.
- The Israel-Hamas conflict and broader regional tensions could disrupt employees, suppliers, operations and logistics. The company also faces NIS currency exposure; hedging reduces but does not eliminate it.
- Other material business risks include product and technology changes, competition, subscription renewals, cybersecurity, privacy and human-rights concerns, AI regulation, and export-control requirements.
- Fair-value liabilities at year-end included $54.1 million for warrants, $47.2 million for restricted sponsor shares and $81.7 million for price-adjustment shares. Remeasurement can materially affect GAAP earnings without reflecting current operating performance.
- The company said it had no legal proceedings expected to have a material effect and no claims requiring accrual at year-end. It disclosed a former consultant’s claims in its risk discussion. Separately, it withdrew certain Israeli tax-ruling applications and undertook to indemnify specified former TWC parties for certain Israeli taxes, costs and expenses if triggered.
- Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023. The auditor did not provide an internal-control attestation, as the company remains an emerging growth company.
Important facts for investors to verify
- Whether ARR growth and retention trends translate into recognized subscription revenue and sustained cash generation.
- The assumptions and potential earnings volatility associated with the fair-value liabilities, including the warrant and sponsor-share instruments.
- Customer and operational exposure to government budgets, the Israel conflict, foreign-exchange movements and export restrictions.
- Potential dilution from outstanding equity awards, warrants and earnout-related shares; SUNCORPORATION held approximately 47% of shares at year-end.
- The status and potential financial effect of the Israeli tax indemnification undertaking and the consultant-related claims.